Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, November 18, 2026

Longitudinal dynamics of serum neurofilament light chain and prognostic value for functional outcome after acute stroke: a prospective cohort study

 Predictions are useless! 

Survivors want 100% recovery protocols  and YOU'RE SO FUCKING INCOMPETENT YOU DIDN'T DELIVER THEM!

Longitudinal dynamics of serum neurofilament light chain and prognostic value for functional outcome after acute stroke: a prospective cohort study


  • 1. Department of Neurology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

  • 2. The First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China

Abstract

Background: 


Serum neurofilament light chain (sNfL) is a blood biomarker of neuroaxonal injury, but its early longitudinal dynamics and prognostic value in clinically heterogeneous acute stroke populations remain insufficiently defined. This study characterized early sNfL changes and examined their association with functional outcome after acute stroke.


Methods: 


This prospective cohort study consecutively enrolled 104 patients with acute stroke and 86 healthy controls (HCs) between January 2023 and December 2024. Patients were grouped as intracerebral hemorrhage (ICH, n = 28), ischemic stroke treated with intravenous thrombolysis (IS+IVT, n = 33), and ischemic stroke without intravenous thrombolysis (IS−IVT, n = 43). sNfL was measured within 24 h after onset (D1) and on day 7 (D7). Functional outcome was assessed by modified Rankin Scale (mRS) at 3 and 6 months. Linear mixed-effects models assessed longitudinal sNfL trajectories. Multivariable logistic regression assessed prognostic associations, with the 3-month outcome as the primary endpoint and the 6-month outcome as the secondary endpoint. Restricted cubic spline (RCS) and interaction analyses were exploratory.


Results: 


sNfL increased significantly from D1 to D7 (p < 0.001) and was higher in patients with stroke than in HCs at D1 (p < 0.001). In the linear mixed-effects model adjusted for age and admission National Institutes of Health Stroke Scale (NIHSS) score, longitudinal sNfL trajectories did not differ significantly among the clinical stroke groups (time × group interaction, p = 0.225). The predominantly mild-to-moderate severity profile may have limited the detection of trajectory differences. In multivariable logistic regression, each 10-pg/mL increase in D1 sNfL was associated with 5% higher odds of poor functional outcome at 3 months (OR = 1.05; 95% CI, 1.00–1.12; p = 0.047) and 7% higher odds at 6 months (OR = 1.07; 95% CI, 1.01–1.14; p = 0.025). D7 sNfL was not independently associated with poor functional outcome after adjustment. Exploratory RCS analyses found no statistical evidence of nonlinearity for D1 sNfL and suggested a nonlinear association between D7 sNfL and 3-month poor functional outcome.


Conclusion: 


sNfL levels increased during the first week after acute stroke. Higher D1 sNfL was associated with poor functional outcome at 3 and 6 months, suggesting potential value for early prognostic assessment.

No comments:

Post a Comment